| Recruiting | Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predomin Chronic Neuropathic Pain | Phase 1 / Phase 2 | 2025-10-01 |
| Active Not Recruiting | Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term) Kidney Transplant Rejection, End Stage Renal Disease | — | 2023-08-15 |
| Active Not Recruiting | Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST Blood and Lymphatic Diseases | — | 2021-12-21 |
| Enrolling By Invitation | Long-Term Follow-up of Subjects Who Were Treated With ST-920 Fabry Disease, Fabry Disease, Cardiac Variant | — | 2021-08-16 |
| Active Not Recruiting | Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant R Kidney Transplant Rejection, End Stage Renal Disease | Phase 1 / Phase 2 | 2021-03-17 |
| Active Not Recruiting | Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II | — | 2020-11-03 |
| Completed | Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Diseas Fabry Disease | Phase 1 / Phase 2 | 2019-07-23 |
| Completed | A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Tra Sickle Cell Disease | Phase 1 / Phase 2 | 2019-03-06 |
| Completed | A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta Transfusion Dependent Beta-thalassemia | Phase 1 / Phase 2 | 2018-03-29 |
| Terminated | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With M MPS I | Phase 1 / Phase 2 | 2017-05-24 |
| Terminated | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With M Mucopolysaccharidosis II, MPS II | Phase 1 / Phase 2 | 2017-05-11 |
| Terminated | Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemo Hemophilia B | Phase 1 | 2016-11-15 |
| Completed | Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART Human Immunodeficiency Virus (HIV) | Phase 1 / Phase 2 | 2014-08-01 |
| Completed | Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T HIV | Phase 1 / Phase 2 | 2011-12-01 |
| Terminated | Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T HIV-1-infection | — | 2011-03-18 |
| Completed | Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Sub HIV, HIV Infection | Phase 1 / Phase 2 | 2010-11-01 |
| Completed | Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucle HIV Infection, HIV Infections | Phase 1 | 2009-12-01 |
| Completed | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy | Phase 2 | 2009-11-01 |
| Completed | Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease Idiopathic Parkinson's Disease | Phase 1 / Phase 2 | 2009-10-29 |
| Completed | Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease Alzheimer's Disease | Phase 2 | 2008-11-01 |
| Completed | Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis | Phase 2 | 2008-09-01 |
| Completed | Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509 Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy | Phase 2 | 2008-01-01 |
| Completed | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy | Phase 2 | 2007-05-01 |
| Completed | Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's D Idiopathic Parkinson's Disease | Phase 2 | 2006-11-01 |
| Completed | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy | Phase 2 | 2006-11-01 |
| Completed | Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease Parkinson's Disease | Phase 1 | 2005-06-01 |
| Completed | Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy Diabetic Neuropathy | Phase 1 | 2005-04-01 |
| Completed | CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease Alzheimer's Disease | Phase 1 | 2004-06-01 |